Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colonoscopy & upper endoscopy cases in Oregon: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 1% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 240 | 41,008 | 50% |
| 2020 | 227 | 31,967 | 51% |
| 2021 |
Diagnostic and therapeutic colonoscopy and EGD; identifies every active endoscopist. Professional codes (what the surgeon bills): CPT 45378, 45380, 45385, 45390, 43239, 43235, 43251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 16% of the cases CMS names in Oregon; 135 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 1,451 | 361,322+0.6%/yr | +0.6%/yr | 112.0 | 55% | 413,200 in 2030+2.3%/yr |
| Washington | 393 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| ERCP & endoscopic ultrasound | 26 | 1,050−5.1%/yr | −5.1%/yr | 2.60.7× | 0% | 1,370 in 2030+4.6%/yr |
| Bronchoscopy & lung nodule |
Colonoscopy & upper endoscopy in every state, and its device makers · Every procedure market in Oregon · Every state · Compare with California
| 2024 |
| 35,214 |
| 59% |
| 2025 est. | ≈ 34,700 | – |
| 2026 est. | ≈ 35,700 | – |
| 246 |
| 36,567 |
| 53% |
| 2022 | 247 | 35,785 | 56% |
| 2023 | 256 | 35,196 | 58% |
| 2024 | 259 | 35,214 | 59% |
| 2025 from claims | – | 34,700 31,845–36,712 | 59% |
| 2026 forecast | – | 35,681 31,394–41,175 | 58% |
| 2027 forecast | – | 36,021 30,794–42,926 | 58% |
| 2028 forecast | – | 36,363 30,342–44,526 | 58% |
| 2029 forecast | – | 36,709 29,983–46,037 | 58% |
| 2030 forecast | – | 37,059 29,689–47,490 | 58% |
In 2025, 7% inpatient hospital, 50% hospital outpatient, 43% surgery center. The share outside the hospital has moved −4 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~35,700 | ~2,300 | ~18,200 | ~15,200 |
| 2027 · ~36,000 | ~2,300 | ~18,500 | ~15,200 |
| 2028 · ~36,400 | ~2,400 | ~18,800 | ~15,200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 42% (43% in 2025), hospital outpatient about 52% (50% in 2025).
| 77,215−3.7%/yr |
| −3.7%/yr |
| 104.5 |
| 45% |
| 78,700 in 2030+0.3%/yr |
| Arizona | 351 | 76,510−1%/yr | −1%/yr | 107.4 | 56% | 84,500 in 2030+1.7%/yr |
| Colorado | 277 | 51,857−1.4%/yr | −1.4%/yr | 110.7 | 57% | 56,700 in 2030+1.5%/yr |
| Nevada | 98 | 24,594−2.4%/yr | −2.4%/yr | 89.0 | 70% | 25,500 in 2030+0.6%/yr |
| Utah | 118 | 24,136−2.4%/yr | −2.4%/yr | 114.8 | 32% | 23,500 in 2030−0.5%/yr |
| Idaho | 83 | 19,523−0.2%/yr | −0.2%/yr | 99.4 | 37% | 27,700 in 2030+6%/yr |
| New Mexico | 87 | 16,821−4.2%/yr | −4.2%/yr | 75.9 | 40% | 17,500 in 2030+0.7%/yr |
| Montana | 43 | 13,022−1.4%/yr | −1.4%/yr | 69.9 | 21% | 14,500 in 2030+1.8%/yr |
| Alaska | 57 | 10,213+5.1%/yr | +5.1%/yr | 85.0 | 43% | 11,900 in 2030+2.5%/yr |
| Hawaii | 53 | 9,802−0.3%/yr | −0.3%/yr | 80.0 | 46% | 11,300 in 2030+2.4%/yr |
| Wyoming | 33 | 7,481−3.1%/yr | −3.1%/yr | 69.7 | 54% | 8,320 in 2030+1.8%/yr |
| 10 |
| 796+5.6%/yr |
| +5.6%/yr |
| 1.90.8× |
| 0% |
| 1,500 in 2030+11%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Alcresta Therapeutics leads with 43% of company spending on these surgeons in 2025, +41 pts on 2024.
In 2025, 7 companies reported engagement with Oregon’s surgeons worth $26K in consulting, speaking, meals and travel tied to these products, about $99 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.